Skip to main content
Year archive

IMUGENE LIMITED — 2016 filings

All 52 regulatory filings released by IMUGENE LIMITED (IMU) in 2016, sourced directly from the official regulator.

52 Filings
2016 Period
2016 filings (52)
Filing Released Lang
Investor Newsletter 4 pages 10.6MB
Capital/Financing Update
2016-12-19 English
Imugene progresses mimotope platform 2 pages 242.6KB
Regulatory Filings
2016-12-18 English
Response to ASX Aware Query 8 pages 212.0KB
Regulatory Filings
2016-12-15 English
Acquisition of immuno-oncology technology 4 pages 84.2KB
Regulatory Filings
2016-12-12 English
Response to ASX Price Query 5 pages 424.0KB
Regulatory Filings
2016-12-12 English
Imugene Corporate Presentation 24 pages 7.7MB
Investor Presentation
2016-12-01 English
Response to ASX Price Query 4 pages 179.9KB
Regulatory Filings
2016-11-24 English
Leslie Chong Appointed Chief Executive Officer 2 pages 175.1KB
Board/Management Information
2016-11-20 English
Change of Director's Interest Notice 2 pages 137.4KB
Director's Dealing
2016-11-08 English
Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study 2 pages 179.9KB
Capital/Financing Update
2016-11-06 English
Change in substantial holding 3 pages 148.3KB
Regulatory Filings
2016-11-06 English
Ceasing to be a substantial holder 2 pages 129.3KB
Major Shareholding Notification
2016-11-03 English
Appendix 3B, 708A Notice & Listing Rule 3.10.5A information 14 pages 364.4KB
Capital/Financing Update
2016-11-02 English
AGM Presentation 12 pages 1.5MB
AGM Information
2016-11-01 English
Results of Meeting 1 page 70.0KB
Declaration of Voting Results & Voting Rights Announcements
2016-11-01 English
Becoming a substantial holder 3 pages 144.4KB
Regulatory Filings
2016-10-30 English
Director Resignation - Final Director Interest Notice 3 pages 424.4KB
Board/Management Information
2016-10-30 English
Appendix 3B 12 pages 286.2KB
Capital/Financing Update
2016-10-26 English
Appendix 4C - quarterly 5 pages 282.6KB
Interim / Quarterly Report Q1 2017
2016-10-26 English
Imugene Share Placement raises $3.2 million 2 pages 171.9KB
Capital/Financing Update
2016-10-20 English
Trading Halt 2 pages 277.1KB
Capital/Financing Update
2016-10-18 English
Notice of Annual General Meeting/Proxy Form 27 pages 988.6KB
AGM Information
2016-09-29 English
Annual Report to shareholders 74 pages 612.0KB
Annual Report FY 2016
2016-09-27 English
Appendix 4G 10 pages 300.4KB
Governance Information
2016-09-27 English
Imugene receives $1.3m R&D Tax Refund 1 page 155.0K
Regulatory Filings
2016-09-21 English
Imugene successfully completes preclinical animal studies 1
Regulatory Filings
2016-09-19 English
Imugene Final Cancer Vaccine Doses Delivered to GMP Depot 1
Regulatory Filings
2016-08-29 English
Preliminary Final Report 23 pages 127.6KB
Annual Report FY 2016
2016-08-29 English
Imugene Receives Approval to Start Gastric Cancer Study 2 pages 174.9KB
Regulatory Filings
2016-08-21 English
Imugene Receives Institutional Review Board approval 2 pages 45.2KB
Regulatory Filings
2016-08-10 English
Appendix 4C - quarterly 5 pages 381.9KB
Interim / Quarterly Report Q4 2016
2016-07-28 English
Imugene Receives Institutional Review Board Approval 2 pages 270.6KB
Regulatory Filings
2016-07-10 English
Becoming a substantial holder 3 pages 307.1KB
Major Shareholding Notification
2016-07-05 English
Ceasing to be a substantial holder 2 pages 266.7KB
Major Shareholding Notification
2016-06-14 English
Completes submission to Hospital Ethics Committees 2 pages 140.2KB
Regulatory Filings
2016-05-29 English
Corporate Development Update 1 page 117.1KB
Board/Management Information
2016-05-26 English
Appendix 4C - quarterly 6 pages 663.5KB
Interim / Quarterly Report Q3 2016
2016-04-28 English
Regulatory package submission for Her-Vaxx in Hong Kong 2 pages 141.1KB
Regulatory Filings
2016-04-20 English
Shareholder Newsletter 8 pages 817.8KB
Investor Presentation
2016-04-12 English
Dr Yelena Janjigian appointed as SAB member 1 page
Board/Management Information
2016-04-11 English
Manufacturing Update 2 pages 52.0KB
Regulatory Filings
2016-03-06 English
Half Yearly Report and Accounts 24 pages 719.8KB
Interim / Quarterly Report H1 2016
2016-02-28 English
Imugene Results for December Half Year 3 pages 140.8KB
Interim / Quarterly Report H1 2016
2016-02-28 English
Imugene to present at the RedChip Global Online Conference 2 pages 126.2KB
Investor Presentation
2016-02-09 English
Appendix 4C - quarterly 5 pages 152.7KB
Interim / Quarterly Report Q2 2015
2016-01-26 English
Partnership to Develop Mimotope Immuno-Oncology Platform 3 pages 57.3KB
Regulatory Filings
2016-01-19 English
Final Director's Interest Notice (OB) 2 pages 33.9KB
Director's Dealing
2016-01-17 English
Noble Financial Capital Markets Investor Presentation 1
Investor Presentation
2016-01-14 English
Biotech Showcase Presentation 40 pages 6.3MB
Investor Presentation
2016-01-10 English
Initial Director's Interest Notice AU 2 pages 233.6KB
Director's Dealing
2016-01-06 English
Dr. Anton Uvarov appointed Non-Executive Director 1
Board/Management Information
2016-01-04 English
Stuart Roberts named as Head of Corporate Development 2 pages 51.9KB
Board/Management Information
2016-01-03 English